Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
SGK inhibitors act on serum- and glucocorticoid-regulated kinases (SGKs), a family of three kinases. The founding member, SGK1, was cloned in 1993 as a gene whose transcription rises quickly after glucocorticoid or serum exposure. SGK1, SGK2 and SGK3 are close relatives of protein kinase B (Akt) and become active downstream of phosphoinositide 3-kinase (PI3K) signaling. In kidney epithelia, SGK1 phosphorylates the ubiquitin ligase Nedd4-2 and keeps more epithelial sodium channels (ENaC) at the cell surface. SGK1 is also studied in hypertension, insulin signaling and tumor cell survival. GSK-650394, EMD638683 and SI-113 inhibit SGK1, and GSK-650394 also acts on SGK2. PROTAC SGK3 degrader-1 removes SGK3 through a proteolysis-targeting chimera (PROTAC) design.
308-R-C4-PEG3-C1-Boc is a SGK3 ligand-linker conjugate designed for use in the synthesis of PROTAC SGK3 degrader-2. This compound facilitates targeted protein degradation by effectively linking the SGK3 ligand with a degradation mechanism. Its application in chemical research is particularly valuable for studies involving SGK3 modulation and related cellular pathways.
Out of stock
All 3 sizes
(S,S,S)-VH032 is a ligand for the E3 ubiquitin ligase von Hippel-Lindau (VHL), enabling targeted protein degradation through the formation of PROTACs. It plays a crucial role in the synthesis of PROTAC SGK3 degrader-2, facilitating the selective degradation of SGK3 and other target proteins. This compound is valuable for research in protein regulation and targeted therapeutic strategies.
Out of stock
All 3 sizes